Suzhou Ribo Life Science Co Ltd Sustainability Reports
The company discovers, researches, and develops small nucleic acid and oligonucleotide drugs based on RNA interference technology. Its therapeutic pipeline focuses on cardiovascular, metabolic, renal, and liver diseases.
Sector: Manufacturing
Country: China
Exchange: Hong Kong Stock Exchange
FIGI: BBG01ZBQWBP4
1 reports from 2025 to 2025
